Célia HART

Supernova Invest

Celia has more than 15 years of private equity experience and has been at Supernova Invest since 2005 in charge of the early-stage team, the healthcare sector and the Supernova 2 fund.

Prior to that, she held several senior positions at Cambridge Antibody Technology (Medimmune since its acquisition by Astra Zeneca), one of the UK’s leading biotech companies.

She was involved in the development of numerous therapeutic antibodies, some of which were co-developed with international industrial partners. Celia holds a Master’s degree in Chemistry from the University of Geneva (Switzerland), a PhD from Oxford University, and an MBA from Grenoble Ecole de Management (France).